CD3-HM230 | 价格

CD3-HM230-100μg / 询价

CD3-HM230-500μg / 询价

CD3-HM230-500μgx2 / 询价

Human CD30/TNFRSF8 Protein

产品信息(Product Info)
表达区间及表达系统(Source)

Recombinant Human CD30/TNFRSF8 Protein is expressed from HEK293 with hFc tag at the C-Terminus.
It contains Phe19-Lys379 [Accession | P28908-1].

分子量大小(Molecular Weight)

The protein has a predicted MW of 65.2 kDa. Due to glycosylation, the protein migrates to 80-115 kDa based on Bis-Tris PAGE result.

纯度(Purity)

> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC

内毒素(Endotoxin)

Less than 1EU per μg by the LAL method.

制剂(Formulation)

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

重构方法(Reconstitution)

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

存储(Storage)

-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

产品数据(Assay Data)
Bis-Tris PAGE

Human CD30 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

The purity of Human CD30 is greater than 95% as determined by SEC-HPLC.

ELISA Data

Immobilized Human CD30 Ligand, His Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Human CD30, hFc Tag with the EC50 of 3.8ng/ml determined by ELISA.

背景(Background)

The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin's lymphomas (NHLs).

分子别名(Synonyms)

CD30; CD30KI-1; CD30L receptor; TNFRSF8; D1S166EKi-1; CD30KI-1

文献(References)

(1) Oflazoglu E, Grewal IS, Gerber H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol. 2009;647:174-85. doi: 10.1007/978-0-387-89520-8_12. PMID: 19760074.

Note: HPLC results always come from liquid protein, due to absorption peak interference of trehalose in lyophilized powder.